Tenofovir DF Monotherapy is Superior to Entecavir-Adefovir Combination in Chronic Hepatitis B Patients who Are Suboptimal Responder for Lamivudine-Adefovir Therapy with RT204I/V Mutation: A Interim Analysis of Prospective Multicenter Trial

2016 ◽  
Vol 64 (2) ◽  
pp. S589
Author(s):  
H.S. Kim ◽  
S.H. Lee ◽  
S.G. Kim ◽  
Y.S. Kim ◽  
S.W. Jeong ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Interim Analysis ◽  
Multicenter Trial ◽  
Tenofovir Df ◽  
Suboptimal Responder ◽  
Prospective Multicenter Trial

1007 RISK OF RENAL TOXICITY WITH TENOFOVIR DF (TDF) FOR CHRONIC HEPATITIS B (CHB)

2010 ◽  
Vol 52 ◽  
pp. S388-S389 ◽  
Author(s):  
R. Gish ◽  
M. Mangahas ◽  
S. Baqai ◽  
R. Shaw
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Renal Toxicity ◽  
Tenofovir Df

Long-term lamivudine treatment in anti-HBe positive chronic hepatitis B: an interim analysis

2001 ◽  
Vol 34 ◽  
pp. 132-133
Author(s):  
T. Santantonio ◽  
E. Sinisi ◽  
M. Mazzola ◽  
M. Insalata ◽  
A. Guastadisegni ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Interim Analysis ◽  
Lamivudine Treatment ◽  
Positive Chronic Hepatitis
Sign in / Sign up

Export Citation Format

Share Document